Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
Benefiting from the continuously clarifying underlying biology of immune checkpoints and ligand–receptor interactions, the emergence of new anticancer treatment strategy, immunotherapy has shown substantial benefits on several liquid and solid tumors. Immune checkpoint inhibitors (ICIs) can block th...
Main Authors: | Haiyang Wang, Abdulkadir Mustafa, Shixi Liu, Jun Liu, Dan Lv, Hui Yang, Jian Zou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.01254/full |
Similar Items
-
Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01) -
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
by: Lucas V. dos Santos, et al.
Published: (2021-03-01) -
Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation
by: Shicong Zhu, et al.
Published: (2020-09-01) -
Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review
by: Xiaolin Liu, et al.
Published: (2020-12-01) -
Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
by: Niki Karachaliou, et al.
Published: (2015-06-01)